Feasibility Study on Treating Bronchial Asthma with Spleen Intervention Syndrom
10.3969/j.issn.1005-1678.2017.08.140
- VernacularTitle:天晴速乐联合舒利迭治疗支气管哮喘-慢阻肺重叠综合征的可行性研究
- Author:
Zhihui DAI
;
Changxi FENG
;
Yingying LUO
- Keywords:
tiotropium bromide aerosol;
salmeterol texasone aerosol;
ACOS;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(8):329-330
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of tiotropium bromide aerosol combined with salmeterol in the treatment of ACOS. Methods 76 patients with ACOS were enrolled in this study from October 2014 to November 2016. They were divided into experimental group and control group according to the random number table method. The test group was given tiotropium bromide combined with salmeterol Casson aerosol treatment, the control group was given salmeterol tacrolone aerosol treatment, compared the two groups of patients with clinical efficacy and adverse reactions. Results The total effective rate was 92.11% in the experimental group and 73.68% in the control group, the difference was statistically significant (Z = 4.547, P<0.05). The ACT score of the test group was higher than that of the control group, the CAT score was lower than that of the control group, the difference was statistically significant (P<0.05); The incidence of adverse reactions in the test group was 10.53%, the incidence of adverse reactions in the control group was 13.16%,the difference was not statistically significant (χ2 = 0.126). Conclusion Tiotropium powder combined with salmeterol tegon aerosol in the treatment of bronchial asthma-chronic obstructive pulmonary syndrome is reliable and worthy of clinical practice.
